GoodRx rounds up 14 new weight loss drugs
A GoodRx roundup of newer weight loss medications. Only the title came through, so tap through for the full list and details.
Recap by typeshit. Full story at GoodRx.
Read at GoodRx
More peptides
-
A look at whether the munchies feel different for people on a GLP-1 
A look at whether the munchies feel different for people on a GLP-1
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
-
63 & Counting on going from 270 to 222 pounds on tirzepatide in six months 
11:37
63 & Counting on going from 270 to 222 pounds on tirzepatide in six months
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
-
Philstar Life on celebrities and the weight loss drug Ozempic Philstar Life on celebrities and the weight loss drug Ozempic
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
-
Food and agribusiness expert says fibre is gaining ground with the GLP-1 trend 
Food and agribusiness expert says fibre is gaining ground with the GLP-1 trend
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
-
Neil Iyengar and an oncology panel weigh GLP-1 safety for breast cancer patients Neil Iyengar and an oncology panel weigh GLP-1 safety for breast cancer patients
CancerNetwork brought together oncology clinicians and a pharmacist to discuss whether GLP-1 drugs are safe for people with breast cancer.
-
Oasis testing says Peptides For Sale passed none of 23 gray-market peptide tests peptides typeshitSafetyOasis testing says Peptides For Sale passed none of 23 gray-market peptide tests
Oasis reports failures including wrong compounds, low purity and off-label doses in BPC-157, semaglutide and Melanotan II, and says Peptide Gurus passed 9 of 46.
